1 – 10 of 21
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Liproca Depot : A New Antiandrogen Treatment for Active Surveillance Patients
(
- Contribution to journal › Article
-
Mark
Population-based randomized trial of screening for clinically significant prostate cancer ProScreen : a pilot study
(
- Contribution to journal › Article
- 2021
-
Mark
Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11
(
- Contribution to journal › Article
- 2019
-
Mark
A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy : An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer
(
- Contribution to journal › Article
-
Mark
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
(
- Contribution to journal › Article
- 2018
-
Mark
Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer : Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial
(
- Contribution to journal › Article
-
Mark
Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases
(
- Contribution to journal › Article
- 2017
-
Mark
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer : Extended Analysis of the Phase 3 PREVAIL Study
(
- Contribution to journal › Article
-
Mark
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301) : An open-label, phase 3, randomised controlled trial
(
- Contribution to journal › Article
- 2016
-
Mark
Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.
(
- Contribution to journal › Article